Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
News headline image
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
From BeiGene
Via Business Wire
News headline image
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: BeiGene Q2 Earnings ↗
  BeiGene (NASDAQ:BGNE) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings BeiGene reported an EPS of $-5.56. 
Via Benzinga
News headline image
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
News headline image
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday ↗
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
BeiGene Reports Second Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
News headline image
Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
News headline image
Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst ↗
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell... 
Via Benzinga
News headline image
U.S. FDA Defers Decision On BeiGene's Filing For Esophageal Carcinoma Due To Pending Inspection ↗
The U.S. Food and Drug Administration (FDA) has deferred decision on the Biologics License Application (BLA) for BeiGene’s (NASDAQ: BGNE) tislelizumab as a second-line treatment for patients with... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
From BeiGene
Via Business Wire
News headline image
BeiGene Appoints Chan Lee as General Counsel
From BeiGene
Via Business Wire
News headline image
Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments ↗
New investments in China life science may have declined over the last year, but large investment companies continue to raise large sums to invest. Sequoia China has raised about $9 billion to make... 
Via Talk Markets
News headline image
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
From BeiGene
Via Business Wire
News headline image
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates ↗
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development... 
Via Talk Markets
News headline image
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
News headline image
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study ↗
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal... 
Via Benzinga
News headline image
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
News headline image
7 Penny Stocks That Could Triple in 2022 ↗
Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns. 
Via InvestorPlace
News headline image
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
News headline image
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch ↗
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. 
Via Benzinga
News headline image
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
From BeiGene
Via Business Wire
News headline image
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
From BeiGene
Via Business Wire
News headline image
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
From BeiGene
Via Business Wire
News headline image
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
From BeiGene
Via Business Wire
News headline image
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
From BeiGene
Via Business Wire
News headline image
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
From BeiGene
Via Business Wire
News headline image
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
From BeiGene, Ltd.
Via Business Wire
News headline image
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.